The spectrum of antibody-mediated renal allograft injury: implications for treatment.
about
Proteasome inhibitors in progressive renal diseasesThe inferior impact of antibody-mediated rejection on the clinical outcome of kidney allografts that develop de novo thrombotic microangiopathy.Molecular phenotypes of acute rejection predict kidney graft prognosis.Neutralizing BAFF/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model.The generation and maintenance of serum alloantibody.Preexisting donor-specific HLA antibodies predict outcome in kidney transplantationPicking transplant glomerulopathy out of the CAN: evidence from a clinico-pathological evaluationThe link between major histocompatibility complex antibodies and cell proliferation.Surveillance of alloantibodies after transplantation identifies the risk of chronic rejection.Graft-derived CCL2 increases graft injury during antibody-mediated rejection of cardiac allografts.Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation setsAntibody-mediated rejection of single class I MHC-disparate cardiac allografts.Pathological diagnosis of antibody-mediated rejection in renal allograft without c4d staining, how much reliable?Enhanced de novo alloantibody and antibody-mediated injury in rhesus macaques.Rituximab in the treatment of refractory late acute antibody-mediated rejection: Our initial experience.Anti-huCD20 antibody therapy for antibody-mediated rejection of renal allografts in a mouse model.Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantationPolymorphism of leukocyte and erythrocyte antigens in chronic kidney disease patients in southern Brazil.Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-κB signaling in endothelial cells.Calculated PRA (CPRA): the new measure of sensitization for transplant candidates.Noninvasive methods to assess the risk of kidney transplant rejection.Biological agents in kidney transplantation: belatacept is entering the field.New therapeutic approaches to antibody-mediated rejection in renal transplantation.Detection of anti-HLA antibodies by solid-phase assay in kidney transplantation: friend or foe?The impact of donor-specific anti-HLA antibodies on late kidney allograft failure.Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far?The increasing clinical importance of alloantibodies in kidney transplantation.Achieving incompatible transplantation through desensitization: current perspectives and future directions.The Role of Humoral Alloreactivity in Liver Transplantation: Lessons Learned and New Perspectives.Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.Benefits, efficacy, cost-effectiveness and infectious complications in transplant patients desensitized with intravenous immunoglobulin and anti-CD20 therapy.Persistent C4d and antibody-mediated rejection in pediatric renal transplant patients.Preformed donor HLA-DP-specific antibodies mediate acute and chronic antibody-mediated rejection following renal transplantation.Donor-Specific HLA Antibody IgG Subclasses Are Associated with Phenotypes of Antibody-Mediated Rejection in Sensitized Renal Allograft Recipients.Study of the allogeneic response induced by endothelial cells expressing HLA class II after lentiviral transduction.Kidney allograft survival after acute rejection, the value of follow-up biopsies.FR104, an antagonist anti-CD28 monovalent fab' antibody, prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate renal allograft.Mastering the risk of HLA antibodies in kidney transplantation: an algorithm based on pretransplant single-antigen flow bead techniques.Renal Association Clinical Practice Guideline on post-operative care of the kidney transplant recipient.Clinical relevance of the de novo production of anti-HLA antibodies following intestinal and multivisceral transplantation.
P2860
Q27011485-874A3274-60E3-4E99-8F3F-B202730BA29EQ33426548-F36D038A-8C80-49A0-BF0A-2140ED359B8AQ33562254-B8F0796B-057F-48D9-8B67-83E09EDF5AC2Q33891669-F657AA4B-6168-46B0-9783-6BF641FED7F2Q34106158-BD4C0414-3AFE-44D0-AF57-1D9674A4B8A2Q34124202-4639A014-0970-4AD0-A985-99D67E42F64FQ34423734-D55E662B-D7F0-4180-B1DC-A4671768962EQ35223952-7475D474-0D99-4F7F-B6F9-FBF74C5C4FB2Q35669313-5B9C9206-AF68-44EF-81E9-3CA8CE80EE40Q35731399-489C7348-558C-4BA0-83E9-4D7020167646Q35834570-CE690D59-3A16-4DCF-AEE5-6EC1BFF051EFQ36131185-9A810C3E-9027-4055-881E-722428F4E4BCQ36529421-126188B7-6094-4456-B482-74A2A89EAFC2Q36575860-D3A4D5D2-0865-43F1-B98F-16902DE1D3C2Q37241071-F9F1E51E-D6D0-4EB4-B0B6-E544A3902872Q37252758-FD75E9FE-116A-4B77-A3F7-7A8BE224EF9FQ37267474-B6B302FE-D99D-4168-ADD4-45BE17E10567Q37444994-1920FC12-6F1A-4B1B-A9B1-C19765D643C0Q37453921-9E201E13-9CBA-4207-8996-7239669EE47AQ37643767-724DDCC4-4DD5-464F-AD17-F2F9293EA927Q37693693-2150AFB6-5A64-48FF-99F7-07C5FB02FBACQ37781355-E7BF65ED-AF68-4517-8533-531E76322759Q37898509-A7EFA15E-DC8E-406B-86D1-73BABCC39349Q38001495-DF802322-90FE-4CEB-82C3-D3BB5FC4F44EQ38003049-95CAD8E0-B0D1-43E9-9EF1-BBFE49040BC3Q38064659-B6EEF8D6-6AD7-4020-AEB3-8F939EF50F46Q38258153-2C712214-12FC-430B-B82A-98BD35B5CF7EQ38445336-5C51A55F-1CA1-42E8-8317-20EA3AF94758Q39121357-86AD48FB-3EF0-4A84-A3A0-F977CE62E90FQ40198753-B4CD6042-5897-4933-875A-CF65AF8BCEC8Q41577805-E9F0DF9C-F7A0-42D5-A6BC-7FA470EF0F43Q42682772-F68B513E-CD03-49DE-87A3-11D484CE95A9Q42838879-8FF5E048-CEDE-4216-A7AB-A5BCA007EE46Q43110440-1AF55361-41B4-4BEF-B837-1142F1798208Q43442503-A976019F-0EA7-4DD8-93A4-9DFE254C11A8Q46211382-81CCB696-C935-4E27-8B38-AB531A9B62BDQ51026715-DF5C0058-D4CC-433E-B326-F16E7B1BD278Q51558707-306E0F6A-C79A-4991-9896-00160A1245B3Q52845695-166135C2-132B-4F28-84AD-6FFB47BC9066Q52881666-3997894B-9503-4C67-8FD7-36C7CBD94B60
P2860
The spectrum of antibody-mediated renal allograft injury: implications for treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The spectrum of antibody-mediated renal allograft injury: implications for treatment.
@en
The spectrum of antibody-mediated renal allograft injury: implications for treatment.
@nl
type
label
The spectrum of antibody-mediated renal allograft injury: implications for treatment.
@en
The spectrum of antibody-mediated renal allograft injury: implications for treatment.
@nl
prefLabel
The spectrum of antibody-mediated renal allograft injury: implications for treatment.
@en
The spectrum of antibody-mediated renal allograft injury: implications for treatment.
@nl
P2093
P2860
P1476
The spectrum of antibody-mediated renal allograft injury: implications for treatment.
@en
P2093
P2860
P304
P356
10.1111/J.1600-6143.2008.02262.X
P407
P577
2008-07-01T00:00:00Z